A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers
Latest Information Update: 02 Sep 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Regorafenib (Primary) ; Trametinib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CheckMate9N9
- Sponsors Bristol-Myers Squibb
- 31 Aug 2024 This trial has been completed in Czechia according to European Clinical Trials Database record.
- 19 Aug 2024 Planned End Date changed from 11 Mar 2024 to 15 Oct 2024.
- 26 Sep 2023 Planned End Date changed from 30 Jan 2026 to 11 Mar 2024.